{
    "clinical_study": {
        "@rank": "38419", 
        "arm_group": {
            "arm_group_label": "Low Molecular Weight Heparin"
        }, 
        "brief_summary": {
            "textblock": "The study purpose is to document the prescription and the use of Low Molecular Weight\n      Heparin in usual medical practice in patients with cancer and established Venous\n      Thromboembolism. This study also aims at gathering epidemiological data on the Low Molecular\n      Weight Heparin therapy of Venous Thromboembolism in patients with cancer."
        }, 
        "brief_title": "Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Venous Thromboembolism", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must provide informed consent\n\n          -  Men or women aged 18 years or more\n\n          -  Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low\n             Molecular Weight Heparin before entry into the study\n\n        Exclusion Criteria:\n\n        - Contraindication to the use of Low Molecular Weight Heparin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Men or women aged 18 years or more with on-going cancer and recent diagnosis of Venous\n        Thromboembolism, treated with Low Molecular Weight Heparin before entry into the study"
            }
        }, 
        "enrollment": {
            "#text": "419", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803022", 
            "org_study_id": "Tropique"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin", 
                "Heparin, Low-Molecular-Weight", 
                "Dalteparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Venous Thromboembolism", 
            "Cancer", 
            "Low Molecular Weight Heparin"
        ], 
        "lastchanged_date": "September 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75010"
                }, 
                "name": "Hopital Saint Louis"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer", 
        "overall_official": {
            "affiliation": "Groupe Francophone Thrombose et Cancer", 
            "last_name": "Dominique Farge Bancel, Pr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
                "France:Comit\u00e9 National Informatique et Libert\u00e9"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Prescription conditions and use of Low Molecular Weight Heparin in the French usual practice for the treatment of symptomatic Venous Thromboembolism in  patients with cancer at up to 6  months", 
            "safety_issue": "No", 
            "time_frame": "up to 6  months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate the consistency of the Low Molecular Weight Heparin use with French national recommendations on the treatment of Venous Thromboembolism in patients with cancer.", 
                "safety_issue": "No", 
                "time_frame": "up to 6  months"
            }, 
            {
                "measure": "To evaluate Venous Thromboembolism recurrences, bleeding, thrombocytopenia and deaths during Low Molecular Weight Heparin treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 6  months"
            }, 
            {
                "measure": "To describe clinical factors associated with treatment duration with Low Molecular Weight Heparin and those associated with the occurrence of Venous Thromboembolism in patients with cancer", 
                "safety_issue": "No", 
                "time_frame": "up to 6  months"
            }, 
            {
                "measure": "To evaluate the anticoagulant treatment perception and satisfaction by patients with cancer disease with a validated questionnaire", 
                "safety_issue": "No", 
                "time_frame": "up to 6  months"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}